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Class I MHC molecules are under diversifying selection but share the 
preference for binding to conserved areas of human proteins, and most target 
human viruses with similar efficiency.  However flaviviruses, such as Hepatitis 
C, are unusual in that non-conserved areas may be preferentially targeted.   
MHC binding can therefore be considered as ‘nature’s estimator of sequence 
conservation/functionality’ and this acts a fundamental force shaping the 
adaptation of pathogens and different viruses have taken different strategies 
to escape these selective pressures. 
 
Some individuals exposed to Hepatitis C clear the virus during acute infection 
while others become chronically infected and there is also intra-patent 
variability in the response to therapy.  This is likely to be determined by both 
variability in host alleles and the degree to which the infecting virus has 
adapted to those responses.   However, to predict likely clinical outcomes it is 
also essential to first understand which responses are effective and 
constraining the virus from those host responses which are being elicited by 
the virus and are non-effective or even harmful to the host.     
 
The failure of the STEP trial of the Merck developed Ad5-based HIV vaccine, 
which demonstrated that HIV acquisition was unexpectedly enhanced in 
vaccinated individuals despite evidence of good immunogenicity has created 
new challenges in HIV vaccine research.  We have found evidence of 
characteristic HLA allele-specific adaptations that induce T cell responses that 
are not just ineffective or neutral but actively enhancing to viral infection and 
harmful to immune control. These responses may appear strong by standard 
measures but they represent the consequence rather than the cause of 
adaptation and as such, serve the interests of the virus rather than the host. 
These findings support the concept that the more generally 'immunogenic' a 
vaccine is to this highly adaptable pathogen, the greater harm the vaccine 
may do unless the enhancing viral elements are pre-emptively identified and 
excluded from the immunogen. 
 
 
